The biology and function of fibroblasts in cancer

Nature Reviews Cancer

Volumn 16, Issue 9, 2016, Pages 582-598

  Kalluri, Raghu ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GROWTH FACTOR; CYTOKINE; TUMOR PROTEIN;

ADIPOCYTE; ANGIOGENESIS; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CARCINOMA IN SITU; CARTILAGE CELL; CELL FUNCTION; CELL HETEROGENEITY; CELL METABOLISM; CELL PLASTICITY; CELL SURVIVAL; CYTOLOGY; DRUG TARGETING; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; GENETIC REGULATION; HUMAN; IMMUNE RESPONSE; INDUCED PLURIPOTENT STEM CELL; MESENCHYMAL STEM CELL; METASTASIS; NEOPLASM; NONHUMAN; NUCLEAR REPROGRAMMING; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TISSUE INJURY; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; WOUND HEALING; CELL DIFFERENTIATION; CELL LINEAGE; DISEASE COURSE; DRUG RESISTANCE; FORECASTING; GENETIC EPIGENESIS; IMMUNOLOGY; MESENCHYMAL STROMA CELL; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); STROMA CELL; VASCULARIZATION;

CELL DIFFERENTIATION; CELL LINEAGE; CYTOKINES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; FORECASTING; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STROMAL CELLS; TUMOR MICROENVIRONMENT; WOUND HEALING;

EID: 84984694266     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.73     Document Type: Review

References (240)

1. Hanahan, D. Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Ronnov-Jessen, L., Petersen, O. W. & Bissell, M. J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 76, 69-125 (1996).
3. Vong, S. & Kalluri, R. The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes Cancer 2, 1139-1145 (2011).
4. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437 (2013).
5. Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3, 422-433 (2003).
6. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
7. Pietras, K. & Ostman, A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316, 1324-1331 (2010).
8. Bhowmick, N. A. et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851 (2004).
9. Lujambio, A. et al. Non-cell-autonomous tumor suppression by p53. Cell 153, 449-460 (2013).
10. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
11. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401 (2006).
12. Ohlund, D., Elyada, E. & Tuveson, D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 211, 1503-1523 (2014).
13. Marsh, T., Pietras, K. & McAllister, S. S. Fibroblasts as architects of cancer pathogenesis. Biochim. Biophys. Acta 1832, 1070-1078 (2013).
14. Ostman, A. & Augsten, M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 19, 67-73 (2009).
15. Tampe, B. & Zeisberg, M. Contribution of genetics and epigenetics to progression of kidney fibrosis. Nephrol. Dial. Transpl. 29 (Suppl. 4), iv72-iv79 (2013).
16. Zeisberg, E. M. & Zeisberg, M. The role of promoter hypermethylation in fibroblast activation and fibrogenesis. J. Pathol. 229, 264-273 (2013).
17. Micallef, L. et al. The myofibroblast, multiple origins for major roles in normal and pathological tissue repair. Fibrogenesis Tissue Repair 5, S5 (2012).
18. Ronnov-Jessen, L. & Petersen, O. W. Induction of α-smooth muscle actin by transforming growth factor-β1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. 68, 696-707 (1993).
19. Paunescu, V. et al. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J. Cell. Mol. Med. 15, 635-646 (2011).
20. Sappino, A. P., Skalli, O., Jackson, B., Schurch, W. & Gabbiani, G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer 41, 707-712 (1988).
21. Powell, D. W. et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. Physiol. 277, C1-C9 (1999).
22. LeBleu, V. S. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047-1053 (2013).
23. Zeisberg, M., Strutz, F. & Muller, G. A. Role of fibroblast activation in inducing interstitial fibrosis. J. Nephrol. 13 (Suppl. 3), S111-S120 (2000).
24. Desmouliere, A., Darby, I. A. & Gabbiani, G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab. Invest. 83, 1689-1707 (2003).
25. Lajiness, J. D. & Conway, S. J. The dynamic role of cardiac fibroblasts in development and disease. J. Cardiovasc. Transl Res. 5, 739-748 (2012).
26. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659 (1986).
27. Monaco, J. L. & Lawrence, W. T. Acute wound healing an overview. Clin. Plast. Surg. 30, 1-12 (2003).
28. Gurtner, G. C., Werner, S., Barrandon, Y. & Longaker, M. T. Wound repair and regeneration. Nature 453, 314-321 (2008).
29. Bliss, L. A. et al. Use of postmortem human dura mater and scalp for deriving human fibroblast cultures. PLoS One 7, e45282 (2012).
30. Virchow, R. Die Cellularpathologie in lhrer Begruendung auf Physiologische und Pathologische Gewebelehre (ed. Hirschwald, A.) (Berlin,1858).
31. Duvall, M. Atlas dEmbryologie. (ed. Masson, G.) (Paris, 1879).
32. Tarin, D. & Croft, C. B. Ultrastructural features of wound healing in mouse skin. J. Anat. 105, 189-190 (1969).
33. Gabbiani, G., Ryan, G. B. & Majne, G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 27, 549-550 (1971).
34. Darby, I. A., Laverdet, B., Bonte, F. & Desmouliere, A. Fibroblasts and myofibroblasts in wound healing. Clin. Cosmet. Investigat. Dermatol. 7, 301-311 (2014).
35. Castor, C. W., Wilson, S. M., Heiss, P. R. & Seidman, J. C. Activation of lung connective tissue cells in vitro. Am. Rev. Respir. Dis. 120, 101-106 (1979).
36. Muller, G. A. & Rodemann, H. P. Characterization of human renal fibroblasts in health and disease: I. Immunophenotyping of cultured tubular epithelial cells and fibroblasts derived from kidneys with histologically proven interstitial fibrosis. Am. J. Kidney Dis. 17, 680-683 (1991).
37. Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. & Brown, R. A. Myofibroblasts and mechanoregulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3, 349-363 (2002).
38. Parsonage, G. et al. A stromal address code defined by fibroblasts. Trends Immunol. 26, 150-156 (2005).
39. Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563 (2007).
40. Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257-272 (2011).
41. Xu, J. et al. Contribution of bone marrow-derived fibrocytes to liver fibrosis. Hepatobiliary Surg. Nutr. 4, 34-47 (2015).
42. Raab, S., Klingenstein, M., Liebau, S. & Linta, L. A. Comparative view on human somatic cell sources for iPSC generation. Stem Cells Int. 2014, 768391 (2014).
43. Lorenz, K. et al. Multilineage differentiation potential of human dermal skin-derived fibroblasts. Exp. Dermatol. 17, 925-932 (2008).
44. Miyake, T. & Kalluri, R. Cardiac biology: cell plasticity helps hearts to repair. Nature 514, 575-576 (2014).
45. Ubil, E. et al. Mesenchymal-endothelial transition contributes to cardiac neovascularization. Nature 514, 585-590 (2014).
46. Sriram, G., Bigliardi, P. L. & Bigliardi-Qi, M. Fibroblast heterogeneity and its implications for engineering organotypic skin models in vitro. Eur. J. Cell Biol. 94, 483-512 (2015).
47. Driskell, R. R. & Watt, F. M. Understanding fibroblast heterogeneity in the skin. Trends Cell Biol. 25, 92-99 (2015).
48. Rodemann, H. P. & Muller, G. A. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am. J. Kidney Dis. 17, 684-686 (1991).
49. Simian, M. et al. The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development 128, 3117-3131 (2001).
50. Wiseman, B. S. & Werb, Z. Stromal effects on mammary gland development and breast cancer. Science 296, 1046-1049 (2002).
51. Driskell, R. R. et al. Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature 504, 277-281 (2013).
52. Dulauroy, S., Di Carlo, S. E., Langa, F., Eberl, G. & Peduto, L. Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat. Med. 18, 1262-1270 (2012).
53. Hamburg-Shields, E., DiNuoscio, G. J., Mullin, N. K., Lafyatis, R. & Atit, R. P. Sustained β-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes. J. Pathol. 235, 686-697 (2015).
54. Rock, J. R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl Acad. Sci. USA 108, E1475-E1483 (2011).
55. De Wever, O., Van Bockstal, M., Mareel, M., Hendrix, A. & Bracke, M. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Semin. Cancer Biol. 25, 33-46 (2014).
56. Dumont, N. et al. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia 15, 249-262 (2013).
57. Ryan, G. B. et al. Myofibroblasts in an avascular fibrous tissue. Lab. Invest. 29, 197-206 (1973).
58. Ryan, G. B. et al. Myofibroblasts in human granulation tissue. Hum. Pathol. 5, 55-67 (1974).
59. Tsukada, T., McNutt, M. A., Ross, R. & Gown, A. M. HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues. Am. J. Pathol. 127, 389-402 (1987).
60. Schor, S. L., Schor, A. M., Grey, A. M. & Rushton, G. Foetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells. J. Cell Sci. 90, 391-399 (1988).
61. Durning, P., Schor, S. L. & Sellwood, R. A. Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro. Lancet 2, 890-892 (1984).
62. Elenbaas, B. & Weinberg, R. A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264, 169-184 (2001).
63. Lohr, M. et al. Transforming growth factor-β1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61, 550-555 (2001).
64. Aoyagi, Y. et al. Overexpression of TGF-β by infiltrated granulocytes correlates with the expression of collagen mRNA in pancreatic cancer. Br. J. Cancer 91, 1316-1326 (2004).
65. Ishii, G., Ochiai, A. & Neri, S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv. Drug Delivery Rev. 99, 186-196 (2015).
66. Bronzert, D. A. et al. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc. Natl Acad. Sci. USA 84, 5763-5767 (1987).
67. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
68. Dvorak, H. F., Form, D. M., Manseau, E. J. & Smith, B. D. Pathogenesis of desmoplasia. I. Immunofluorescence identification and localization of some structural proteins of line 1 and line 10 guinea pig tumors and of healing wounds. J. Natl Cancer Inst. 73, 1195-1205 (1984).
69. Folkman, J. & Kalluri, R. Cancer without disease. Nature 427, 787 (2004).
70. Polyak, K. & Kalluri, R. The role of the microenvironment in mammary gland development and cancer. Cold Spring Harb. Perspect. Biol. 2, a003244 (2010).
71. Erez, N., Truitt, M., Olson, P., Arron, S. T. & Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumorpromoting inflammation in an NF-κB-dependent manner. Cancer Cell 17, 135-147 (2010).
72. Dolberg, D. S., Hollingsworth, R., Hertle, M. & Bissell, M. J. Wounding and its role in RSV-mediated tumor formation. Science 230, 676-678 (1985).
73. Schuh, A. C., Keating, S. J., Monteclaro, F. S., Vogt, P. K. & Breitman, M. L. Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice. Nature 346, 756-760 (1990).
74. Li, J. et al. Idiopathic pulmonary fibrosis will increase the risk of lung cancer. Chinese Med. J. 127, 3142-3149 (2014).
75. Park, J. et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 17, 1216-1219 (2001).
76. Samet, J. M. Does idiopathic pulmonary fibrosis increase lung cancer risk? Am. J. Respir. Crit. Care Med. 161, 1-2 (2000).
77. Sangiovanni, A. et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126, 1005-1014 (2004).
78. Wang, H. M. et al. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. Liver Int. 33, 756-761 (2013).
79. Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725 (1998).
80. Brown, L. F. et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 5, 1041-1056 (1999).
81. Feng, D. et al. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J. Histochem. Cytochem. 48, 545-556 (2000).
82. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989).
83. Giussani, M., Merlino, G., Cappelletti, V., Tagliabue, E. & Daidone, M. G. Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. Semin. Cancer Biol. 35, 3-10 (2015).
84. Chiquet-Ehrismann, R., Mackie, E. J., Pearson, C. A. & Sakakura, T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47, 131-139 (1986).
85. Mackie, E. J. et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc. Natl Acad. Sci. USA 84, 4621-4625 (1987).
86. Kyutoku, M. et al. Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int. J. Mol. Med. 28, 181-186 (2011).
87. Ruan, K., Bao, S. & Ouyang, G. The multifaceted role of periostin in tumorigenesis. Cell. Mol. Life Sci. 66, 2219-2230 (2009).
88. Abdollahi, A. et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 201, 925-935 (2005).
89. Pietras, K., Pahler, J., Bergers, G. & Hanahan, D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 5, e19 (2008).
90. Paulsson, J., Ehnman, M. & Ostman, A. PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol. 10, 1695-1708 (2014).
91. Strutz, F. et al. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 130, 393-405 (1995).
92. Osterreicher, C. H. et al. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc. Natl Acad. Sci. USA 108, 308-313 (2011).
93. Kikuchi, N. et al. Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: an important autocrine/paracrine factor in tumor progression. Cancer Sci. 97, 1061-1069 (2006).
94. Arnold, J. N., Magiera, L., Kraman, M. & Fearon, D. T. Tumoral immune suppression by macrophages expressing fibroblast activation protein-α and heme oxygenase-1. Cancer Immunol. Res. 2, 121-126 (2014).
95. Armulik, A., Genove, G. & Betsholtz, C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21, 193-215 (2011).
96. Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719-734 (2014).
97. Sugimoto, H., Mundel, T. M., Kieran, M. W. & Kalluri, R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 5, 1640-1646 (2006).
98. Guido, C. et al. Metabolic reprogramming of cancerassociated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production. Cell Cycle 11, 3019-3035 (2012).
99. Simpkins, S. A., Hanby, A. M., Holliday, D. L. & Speirs, V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J. Pathol. 227, 490-498 (2012).
100. Goetz, J. G. et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 146, 148-163 (2011).
101. Li, P. et al. Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell Res. 25, 588-603 (2015).
102. Mrazek, A. A. et al. Colorectal cancer-associated fibroblasts are genotypically distinct. Curr. Cancer Ther. Rev. 10, 97-218 (2014).
103. Hu, M. et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 37, 899-905 (2005).
104. Bechtel, W. et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 16, 544-550 (2010).
105. Huang, S. K. et al. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis. 4, e621 (2013).
106. He, Z. et al. Epigenetic regulation of Thy-1 gene expression by histone modification is involved in lipopolysaccharide-induced lung fibroblast proliferation. J. Cell. Mol. Med. 17, 160-167 (2013).
107. Robinson, C. M., Neary, R., Levendale, A., Watson, C. J. & Baugh, J. A. Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with Thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respir. Res. 13, 74 (2012).
108. Zong, Y. et al. Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc. Natl Acad. Sci. USA 109, E3395-E3404 (2012).
109. Albrengues, J. et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancerassociated fibroblasts. Nat. Commun. 6, 10204 (2015).
110. Madar, S. et al. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis 30, 20-27 (2009).
111. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005).
112. Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011 (1999).
113. Dimanche-Boitrel, M. T. et al. In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumorassociated myofibroblasts. Int. J. Cancer 56, 512-521 (1994).
114. Scherz-Shouval, R. et al. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell 158, 564-578 (2014).
115. Calvo, F. et al. Mechanotransduction and YAPdependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15, 637-646 (2013).
116. Procopio, M. G. et al. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat. Cell Biol. 17, 1193-1204 (2015).
117. Boire, A. et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313 (2005).
118. Stetler-Stevenson, W. G., Aznavoorian, S. & Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9, 541-573 (1993).
119. Sternlicht, M. D. et al. The stromal proteinase MMP3/ stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137-146 (1999).
120. Lochter, A. et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 139, 1861-1872 (1997).
121. Borges, F. T. et al. TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J. Am. Soc. Nephrol. 24, 385-392 (2013).
122. Kahlert, C. & Kalluri, R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J. Mol. Med. (Berl.) 91, 431-437 (2013).
123. Luga, V. & Wrana, J. L. Tumor-stroma interaction: revealing fibroblast-secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in cancer metastasis. Cancer Res. 73, 6843-6847 (2013).
124. Hu, Y. et al. Fibroblast-derived exosomes contribute to chemoresistance through priming cancer stem cells in colorectal cancer. PLoS One 10, e0125625 (2015).
125. Shimoda, M. et al. Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat. Cell Biol. 16, 889-901 (2014).
126. Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85-89 (2012).
127. Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476 (2010).
128. Del Pozo Martin, Y. et al. Mesenchymal cancer cellstroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization. Cell Rep. 13, 2456-2469 (2015).
129. Chen, W. J. et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat. Commun. 5, 3472 (2014).
130. Elkabets, M. et al. Human tumors instigate granulinexpressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J. Clin. Invest. 121, 784-799 (2011).
131. Bruzzese, F. et al. Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15. Cancer Res. 74, 3408-3417 (2014).
132. Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891-906 (2009).
133. Gaggioli, C. et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 9, 1392-1400 (2007).
134. OConnell, J. T. et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc. Natl Acad. Sci. USA 108, 16002-16007 (2011).
135. Olaso, E. et al. Tumor-dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. Hepatology 26, 634-642 (1997).
136. Calon, A. et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571-584 (2012).
137. Pena, C. et al. STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer. Cancer Res. 73, 1287-1297 (2013).
138. Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
139. Grum-Schwensen, B. et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res. 65, 3772-3780 (2005).
140. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
141. Martinez-Outschoorn, U. E., Lisanti, M. P. & Sotgia, F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 25, 47-60 (2014).
142. Zhang, D. et al. Metabolic reprogramming of cancerassociated fibroblasts by IDH3α downregulation. Cell Rep. 10, 1335-1348 (2015).
143. Chaudhri, V. K. et al. Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor. Mol. Cancer Res. 11, 579-592 (2013).
144. Pavlides, S. et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8, 3984-4001 (2009).
145. LeBleu, V. S. et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 992-1003, 1001-1015 (2014).
146. Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670 (2012).
147. Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628-632 (2014).
148. Fiaschi, T. et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumorstroma interplay. Cancer Res. 72, 5130-5140 (2012).
149. Valencia, T. et al. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell 26, 121-135 (2014).
150. Kuchnio, A. et al. The cancer cell oxygen sensor PHD2 promotes metastasis via activation of cancer-associated fibroblasts. Cell Rep. 12, 992-1005 (2015).
151. Madsen, C. D. et al. Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis. EMBO Rep. 16, 1394-1408 (2015).
152. Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229-1241 (2015).
153. Ghesquiere, B., Wong, B. W., Kuchnio, A. & Carmeliet, P. Metabolism of stromal and immune cells in health and disease. Nature 511, 167-176 (2014).
154. Molon, B., Cali, B. & Viola, A. T. Cells and cancer: how metabolism shapes immunity. Front. Immunol. 7, 20 (2016).
155. Turley, S. J., Cremasco, V. & Astarita, J. L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669-682 (2015).
156. Lisanti, M. P., Martinez-Outschoorn, U. E. & Sotgia, F. Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. Cell Cycle 12, 2723-2732 (2013).
157. Costea, D. E. et al. Identification of two distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral squamous cell carcinoma. Cancer Res. 73, 3888-3901 (2013).
158. De Boeck, A. et al. Differential secretome analysis of cancer-associated fibroblasts and bone marrowderived precursors to identify microenvironmental regulators of colon cancer progression. Proteomics 13, 379-388 (2013).
159. Koczorowska, M. M. et al. Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol. Oncol. 10, 40-58 (2015).
160. Lotti, F. et al. Chemotherapy activates cancerassociated fibroblasts to maintain colorectal cancerinitiating cells by IL-17A. J. Exp. Med. 210, 2851-2872 (2013).
161. Raffaghello, L. & Dazzi, F. Classification and biology of tumour associated stromal cells. Immunol. Lett. 168, 175-182 (2015).
162. Harper, J. & Sainson, R. C. Regulation of the antitumour immune response by cancer-associated fibroblasts. Semin. Cancer Biol. 25, 69-77 (2014).
163. Patel, R., Filer, A., Barone, F. & Buckley, C. D. Stroma: fertile soil for inflammation. Best practice and research. Clin. Rheumatol. 28, 565-576 (2014).
164. Poggi, A., Musso, A., Dapino, I. & Zocchi, M. R. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol. Lett. 159, 55-72 (2014).
165. Soleymaninejadian, E., Pramanik, K. & Samadian, E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am. J. Reprod. Immunol. 67, 1-8 (2012).
166. Park, S. J. et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173, 3844-3854 (2004).
167. Chomarat, P., Banchereau, J., Davoust, J. & Palucka, A. K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat. Immunol. 1, 510-514 (2000).
168. Hugo, H. J. et al. Contribution of fibroblast and mast cell (afferent) and tumor (efferent) IL-6 effects within the tumor microenvironment. Cancer Microenviron. 5, 83-93 (2012).
169. Wan, Y. Y. & Flavell, R. A. Yin-Yang functions of transforming growth factor-β and T regulatory cells in immune regulation. Immunol. Rev. 220, 199-213 (2007).
170. Bailey, S. R. et al. Th17 cells in cancer: the ultimate identity crisis. Front. Immunol. 5, 276 (2014).
171. Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K. & Flavell, R. A. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24, 99-146 (2006).
172. Kim, J. H. et al. The role of myofibroblasts in upregulation of S100A8 and S100A9 and the differentiation of myeloid cells in the colorectal cancer microenvironment. Biochem. Biophys. Res. Commun. 423, 60-66 (2012).
173. Augsten, M. et al. Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. Cancer Res. 74, 2999-3010 (2014).
174. Mishra, P., Banerjee, D. & Ben-Baruch, A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J. Leukoc. Biol. 89, 31-39 (2011).
175. Van Linthout, S., Miteva, K. & Tschope, C. Crosstalk between fibroblasts and inflammatory cells. Cardiovasc. Res. 102, 258-269 (2014).
176. Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222-225 (2011).
177. Silzle, T. et al. Tumor-associated fibroblasts recruit blood monocytes into tumor tissue. Eur. J. Immunol. 33, 1311-1320 (2003).
178. Barnas, J. L., Simpson-Abelson, M. R., Yokota, S. J., Kelleher, R. J. & Bankert, R. B. T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron. 3, 29-47 (2010).
179. Pinchuk, I. V. et al. PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology 135, 1228-1237 (2008).
180. Nazareth, M. R. et al. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J. Immunol. 178, 5552-5562 (2007).
181. Augsten, M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front. Oncol. 4, 62 (2014).
182. Salmon, H. et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122, 899-910 (2012).
183. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174 (2002).
184. Kraman, M. et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science 330, 827-830 (2010).
185. Wen, Y. et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 101, 2325-2332 (2010).
186. Liao, D., Luo, Y., Markowitz, D., Xiang, R. & Reisfeld, R. A. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 4, e7965 (2009).
187. Ohshio, Y. et al. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. Cancer Sci. 106, 134-142 (2015).
188. Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735-747 (2014).
189. Fidler, I. J. et al. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev. 13, 209-222 (1994).
190. Farmer, P. et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15, 68-74 (2009).
191. Meads, M. B., Gatenby, R. A. & Dalton, W. S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9, 665-674 (2009).
192. Paraiso, K. H. & Smalley, K. S. Fibroblast-mediated drug resistance in cancer. Biochem. Pharmacol. 85, 1033-1041 (2013).
193. Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4, 806-813 (2004).
194. Correia, A. L. & Bissell, M. J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist. Updat. 15, 39-49 (2012).
195. Dittmer, J. & Leyh, B. The impact of tumor stroma on drug response in breast cancer. Semin. Cancer Biol. 31, 3-15 (2015).
196. Mori, Y. et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104, 2149-2154 (2004).
197. Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J. & Bissell, M. J. β1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 68, 4398-4405 (2008).
198. Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J. & Dalton, W. S. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19, 4319-4327 (2000).
199. White, D. E., Rayment, J. H. & Muller, W. J. Addressing the role of cell adhesion in tumor cell dormancy. Cell Cycle 5, 1756-1759 (2006).
200. Hirata, E. et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell 27, 574-588 (2015).
201. Flach, E. H., Rebecca, V. W., Herlyn, M., Smalley, K. S. & Anderson, A. R. Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol. Pharmaceut. 8, 2039-2049 (2011).
202. Li, G., Satyamoorthy, K. & Herlyn, M. N-Cadherinmediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 61, 3819-3825 (2001).
203. Sui, H., Zhu, L., Deng, W. & Li, Q. Epithelialmesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies. Oncol. Res. Treat. 37, 584-589 (2014).
204. Mitra, A., Mishra, L. & Li, S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget 6, 10697-10711 (2015).
205. Chang, J. T. & Mani, S. A. Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. Cancer Lett. 341, 16-23 (2013).
206. Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525-530 (2015).
207. Kumari, N., Dwarakanath, B. S., Das, A. & Bhatt, A. N. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. http://dx.doi. org/10.1007/s13277-016-5098-7 (2016).
208. Wilson, T. R. et al. Widespread potential for growthfactor- driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
209. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
210. Wang, W. et al. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin. Cancer Res. 15, 6630-6638 (2009).
211. McMillin, D. W., Negri, J. M. & Mitsiades, C. S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12, 217-228 (2013).
212. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
213. Madden, J. I. Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer. Infinity Pharmaceuticals http://phx.corporate-ir.net/phoenix.zhtml?c=121941p=irolnewsArticle ID=1653550 (27 January 2012).
214. Jacobetz, M. A. et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62, 112-120 (2013).
215. Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429 (2012).
216. Goel, S., Wong, A. H. & Jain, R. K. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb. Perspect. Med. 2, a006486 (2012).
217. Huang, Y., Goel, S., Duda, D. G., Fukumura, D. & Jain, R. K. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 73, 2943-2948 (2013).
218. Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966-4971 (2004).
219. Cheng, N. et al. Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF-mediated signaling networks. Oncogene 24, 5053-5068 (2005).
220. Lewis, D. A., Travers, J. B., Machado, C., Somani, A. K. & Spandau, D. F. Reversing the aging stromal phenotype prevents carcinoma initiation. Aging 3, 407-416 (2011).
221. Paulsson, J. & Micke, P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin. Cancer Biol. 25, 61-68 (2014).
222. Wang, W. Q. et al. Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer. PLoS One 8, e71189 (2013).
223. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518-527 (2008).
224. Frings, O. et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am. J. Pathol. 182, 2037-2047 (2013).
225. Sherman, M. H. et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80-93 (2014).
226. Takeda, Y., Tsujino, K., Kijima, T. & Kumanogoh, A. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer. Adherence 8, 361-370 (2014).
227. Wang, X. M., Yu, D. M., McCaughan, G. W. & Gorrell, M. D. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 42, 935-945 (2005).
228. Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 6, 13 (2014).
229. Kim, H. Y. et al. Localized smooth muscle differentiation is essential for epithelial bifurcation during branching morphogenesis of the mammalian lung. Dev. Cell 34, 719-726 (2015).
230. Shyer, A. E., Huycke, T. R., Lee, C., Mahadevan, L. & Tabin, C. J. Bending gradients: how the intestinal stem cell gets its home. Cell 161, 569-580 (2015).
231. Selman, M. & Pardo, A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir. Res. 3, 3 (2002).
232. Kalluri, R. & Weinberg, R. A. The basics of epithelialmesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009).
233. Scheel, C. & Weinberg, R. A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 22, 396-403 (2012).
234. Jolly, M. K. et al. Towards elucidating the connection between epithelial-mesenchymal transitions and stemness. J. R. Soc. Interface 11, 20140962 (2014).
235. Chang, H. Y. et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl Acad. Sci. USA 99, 12877-12882 (2002).
236. Hematti, P. Mesenchymal stromal cells and fibroblasts: a case of mistaken identity? Cytotherapy 14, 516-521 (2012).
237. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international Society for Cellular Therapy postition statement. Cytotherapy 8, 315-317 (2006).
238. Albrengues, J. et al. LIF mediates proinvasive activation of stromal fibroblasts in cancer. Cell Rep. 7, 1664-1678 (2014).
239. Avgustinova, A. et al. Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nat. Commun. 7, 10305 (2016).
240. Rajaram, M., Li, J., Egeblad, M. & Powers, R. S. System-wide analysis reveals a complex network of tumor-fibroblast interactions involved in tumorigenicity. PLoS Genet. 9, e1003789 (2013).